Skip to content

La Jolla to publish on Phase 3 blood pressure med trial

May 18, 2017

Investors appear bullish ahead of the publication of Phase 3 data on La Jolla Pharmaceutical’s (LJPC +16.3%) LJPC-501. Results from the ATHOS-3 trial will be published this Sunday, May 21, in the New England Journal of Medicine.

In March, the company announced that the study, in patients with a life-threatening drop in blood pressure, was successful although there were questions about the drug’s effect on mortality.

Previously: LaJolla Pharma under pressure on questions about LJPC-501’s mortality benefit; shares slip 2% (March 13)


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: